Global Influenza Vaccines Market 2021 - 2027

Publisher Name :
Date: 19-Apr-2021
No. of pages: 275

The number of persons being vaccinated with influenza vaccines worldwide will touch the figure of 500 Million by the year-end of 2027

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccines, the introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most of the countries.

Long–term Growth Projection:

• The global influenza vaccines market size is set to surpass US$ 6.5 Billion by the year-end of 2021
• Influenza vaccines demand is expected to increase in the forecast period
• The United States influenza vaccines market is projected to grow with a significant CAGR in the forecast period
• In Japan, the influenza vaccines market holds a rewarding growth opportunity for the future as the demand for the vaccine isgrowing significantly
• The Chinese influenza vaccines market is expected to record a value of nearly US$ 180 Million by the year-end of 2027
• Europe is anticipated to be the fastest-growing market during the forecast period
• The United Kingdom and Germany are the leading revenue generators of the market
• Emerging players backed by technological advancements are developing vaccines that offer a more realistic experience

Key Features of the Study:

• The Market Size of the Global Influenza Vaccines Market with Six Years Forecast
• The Market Size of the Regional and National Influenza Vaccines Market with Six Years Forecast
• Scrutinizes the Global Overall Persons Being Vaccinated with Influenza Vaccines
• Scrutinizes the Regional and National Persons Being Vaccinated with Influenza Vaccines
• Delivers a Latest Happenings in the Global Influenza Vaccines Market
• Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan
• Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Distribution, Exclusive and Licensing Agreement
• Reviews Most Recent Clinical Trials of the Influenza Vaccines
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

The Report Analyses the Market Based on Countries and Presents the Forecast in Terms of Value and Volume for the Next Six Years. Twenty-One Major Markets (21MM) Covered in the Report are as follows:

1) United States
2) Canada
3) Brazil
4) Germany
5) France
6) Italy
7) Spain
8) United Kingdom
9) Netherlands
10) Sweden
11) Denmark
12) Poland
13) Norway
14) Finland
15) Ireland
16) Belgium
17) Australia
18) New Zealand
19) Japan
20) China
21) India

The Report Provides a Comprehensive Analysis of Company Profiles Listed Below:

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus (CSL Limited)
• AstraZeneca
• Mylan
• BioDiem
• Novavax
• Medicago
• Moderna Inc
• Pneumagen
• Daiichi–Sankyo
• Altimmune
• FluGen
• Imutex
• EpiVax
• Versatope Therapeutics, Inc.
• Gamma Vaccines Pty Ltd.
• BiondVax Pharmaceuticals Ltd.
• Hualan Biological Engineering Inc.
• Shanghai Institute of Biological Products Co., Ltd.

The Report Answers Questions Such As:

• What is the current size of the global influenza vaccines market? How much will this market be worth from 2020 to 2027?
• How many persons being vaccinated with influenza vaccines globally during 2015 – 2027?
• Which country is expected to hold the highest market share in theglobal influenza vaccine market?
• What are the main drivers and restraints in the global influenza vaccines market?
• What are the major deals happenings in the global influenza vaccines market?
• Who are the top players and what are their activities, revenue, recent developments, and prospects?
• What are some of the most prominent influenza vaccines currently in development? What are their activities, phase, platform technology, and recent developments?

Global Influenza Vaccines Market 2021 - 2027

Table of Contents

1. Executive Summary

2. Global Number of Persons Vaccinated with Influenza Vaccines and Forecast (2015 – 2027)

3. Global Influenza Vaccines Market Revenue and Forecast (2015 – 2027)

4. Global Influenza Vaccines Market Share and Y–o–Y Growth (%)
4.1 Number of Persons Vaccinated with Influenza Vaccines Share,2015 – 2027(%)
4.2 Influenza Vaccines Market Share,2015 - 2027(%)

5. Global Influenza Vaccines Market Drivers and Inhibitors
5.1 Market Drivers
5.2 Market Inhibitors

6. Global Influenza Vaccines Market, By Geography (Volume and Value),2015 – 2027
6.1 United States
6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.1.2 United States Influenza Vaccines Market Revenue (2015 – 2027)
6.2 Canada
6.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.2.2 Canada Influenza Vaccines Market Revenue (2015 – 2027)
6.3 Germany
6.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.3.2 Germany Influenza Vaccines Market Revenue (2015 – 2027)
6.4 France
6.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.4.2 France Influenza Vaccines Market Revenue (2015 – 2027)
6.5 Italy
6.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.5.2 Italy Influenza Vaccines Market Revenue (2015 – 2027)
6.6 Spain
6.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.6.2 Spain Influenza Vaccines Market Revenue (2015 – 2027)
6.7 United Kingdom
6.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.7.2 United Kingdom Influenza Vaccines Market Revenue (2015 – 2027)
6.8 Netherlands
6.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.8.2 Netherlands Influenza Vaccines Market Revenue (2015 – 2027)
6.9 Sweden
6.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.9.2 Sweden Influenza Vaccines Market Revenue (2015 – 2027)
6.10 Denmark
6.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.10.2 Denmark Influenza Vaccines Market Revenue (2015 – 2027)
6.11 Poland
6.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.11.2 Poland Influenza Vaccines Market Revenue (2015 – 2027)
6.12 Norway
6.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.12.2 Norway Influenza Vaccines Market Revenue (2015 – 2027)
6.13 Finland
6.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.13.2 Finland Influenza Vaccines Market Revenue (2015 – 2027)
6.14 Ireland
6.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.14.2 Ireland Influenza Vaccines Market Revenue (2015 – 2027)
6.15 Belgium
6.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.15.2 Belgium Influenza Vaccines Market Revenue (2015 – 2027)
6.16 Australia
6.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.16.2 Australia Influenza Vaccines Market Revenue (2015 – 2027)
6.17 New Zealand
6.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.17.2 New Zealand Influenza Vaccines Market Revenue (2015 – 2027)
6.18 Japan
6.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.18.2 Japan Influenza Vaccines Market Revenue (2015 – 2027)
6.19 Brazil
6.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.19.2 Brazil Influenza Vaccines Market Revenue (2015 – 2027)
6.20 China
6.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.20.2 China Influenza Vaccines Market Revenue (2015 – 2027)
6.21 India
6.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.21.2 India Influenza Vaccines Market Revenue (2015 – 2027)
6.22 Rest of the World (ROW)
6.22.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)
6.22.2 ROW Influenza Vaccines Market Revenue (2015 – 2027)

7. Recent Development in the Global Influenza Vaccines Market

8. Global Influenza Vaccines Market – Regulatory System
8.1 United States
8.2 Europe
8.3 Japan

9. Major Deals in the Global Influenza Vaccines Market
9.1 Merger and Acquisitions
9.2 Collaboration Deals
9.3 Licensing Agreement
9.4 Exclusive Agreement
9.5 Distribution Agreement

10. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
10.1 Year 2020
10.2 Year 2019

11. Key Companies Analysis
11.1 Sanofi Pasteur
11.1.1 Business Overview
11.1.2 Influenza Vaccines Portfolio
11.1.3 Influenza Vaccines Value Sales Analysis
11.1.4 Promising Influenza Vaccines in the Clinical Development
11.1.5 Recent Development
11.2 GlaxoSmithKline (GSK)
11.2.1 Business Overview
11.2.2 Influenza Vaccines Portfolio
11.2.3 Influenza Vaccines Sales Value Analysis
11.2.4 Recent Development
11.3 Seqirus (CSL Limited)
11.3.1 Business Overview
11.3.2 Influenza Vaccines Portfolios
11.3.3 Influenza Vaccines Sales Value Analysis
11.3.4 Promising Influenza Vaccines in the Clinical Development
11.3.5 Recent Development
11.4 AstraZeneca
11.4.1 Business Overview
11.4.2 Influenza Vaccines Portfolio
11.4.3 Influenza Vaccines Sales Value Analysis
11.4.4 Recent Development
11.5 Gamma Vaccines Pty Ltd
11.5.1 Business Overview
11.5.2 Influenza Vaccines Portfolio
11.5.3 Recent Development
11.6 Hualan Biological Engineering Inc
11.6.1 Business Overview
11.6.2 Influenza Vaccines Portfolio
11.6.3 Recent Development
11.7 Shanghai Institute of Biological Products Co., Ltd.
11.7.1 Business Overview
11.7.2 Influenza Vaccine Portfolio
11.8 Mylan
11.8.1 Business Overview
11.8.2 Influenza Vaccine Portfolio
11.9 BioDiem
11.9.1 Business Overview
11.9.2 Influenza Vaccine Portfolio
11.9.3 Recent Development

12. Emerging Players
12.1 Novavax
12.1.1 Business Overview
12.1.2 Promising Influenza Vaccines in the Clinical Development
12.1.3 Recent Development
12.2 BiondVax Pharmaceuticals Ltd.
12.2.1 Business Overview
12.2.2 Promising Influenza Vaccines in the Clinical Development
12.2.3 Recent Development
12.3 Medicago
12.3.1 Business Overview
12.3.2 Promising Influenza Vaccines in the Clinical Development
12.3.3 Recent Development
12.4 Moderna Inc
12.4.1 Business Overview
12.4.2 Promising Influenza Vaccines in the Clinical Development
12.4.3 Recent Development
12.5 Pneumagen
12.5.1 Business Overview
12.5.2 Promising Influenza Vaccines in the Clinical Development
12.5.3 Recent Development
12.6 Altimmune
12.6.1 Business Overview
12.6.2 Promising Influenza Vaccines in the Clinical Development
12.6.3 Recent Development
12.7 Daiichi Sankyo
12.7.1 Business Overview
12.7.2 Promising Influenza Vaccines in the Clinical Development
12.7.3 Recent Development
12.8 FluGen
12.8.1 Business Overview
12.8.2 Promising Influenza Vaccines in the Clinical Development
12.8.3 Recent Development
12.9 Imutex
12.9.1 Business Overview
12.9.2 Promising Vaccines in the Clinical Development
12.9.3 Recent Development
12.10 EpiVax
12.10.1 Business Overview
12.10.2 Promising Influenza Vaccines in the Clinical Development
12.10.3 Recent Development
12.11 Versatope Therapeutics, Inc.
12.11.1 Business Overview
12.11.2 Promising Influenza Vaccines in the Clinical Development
12.11.3 Recent Development


List of Tables:

Table 4–1: Global Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2015 – 2020
Table 4–2: Global Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2021 – 2027
Table 4–3: Global Influenza Vaccines Market Share (Percent),2015 – 2020
Table 4–4: Global Influenza Vaccines Market Share Forecast (Percent),2021 – 2027
Table 8–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 9–2: Collaboration Deal in the Influenza Vaccines Market
Table 9–3: Licensing Agreement in the Influenza Vaccines Market
Table 9–4: Exclusive Agreement in the Influenza Vaccines Market
Table 9–5: Distribution Agreement in the Influenza Vaccines Market
Table 11–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 11–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 12–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 12–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 12–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 12–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 12–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 12–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 12–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 12–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 12–9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 12–10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 12–11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development


List of Figures:

Figure 2–1: Global Number of Persons Vaccinated with Influenza Vaccines (Thousand),2015 – 2020
Figure 2–2: Global Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2021 – 2027
Figure 3–1: Global Influenza Vaccines Market (Million US$),2015 – 2020
Figure 3–2: Global Influenza Vaccines Market Forecast (Million US$),2021 – 2027
Figure 6–1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–3: United States Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–7: Canada Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–11: Germany Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–15: France Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–16: France Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–19: Italy Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–23: Spain Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–31: Netherlands Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–35: Sweden Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–39: Denmark Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–43: Poland Influenza Vaccines Revenue Market (Million US$),2015 – 2020
Figure 6–44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–47: Norway Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–51: Finland Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–55: Ireland Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–59: Belgium Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–63: Australia Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–67: New Zealand Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–71: Japan Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–75: Brazil Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–79: China Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–80: China Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 6–81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–83: India Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–84: India Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–85: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 – 2020
Figure 6–86: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 – 2027
Figure 6–87: ROW Influenza Vaccines Market Revenue (Million US$),2015 – 2020
Figure 6–88: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2021 – 2027
Figure 11–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
Figure 11–3: GSK Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
Figure 11–5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027
Figure 11–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 – 2020
Figure 11–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2021 – 2027

 

  • 2020-2025 Global Avian Influenza Vaccines Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 27-Apr-2021        Price: US 3360 Onwards        Pages: 112
    Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred. This report elaborates the market size, market characteristics, and market growth of the Avian Influenza Vaccines industry, and bre......
  • Global Influenza Vaccine Sales Market Report 2021
    Published: 21-Apr-2021        Price: US 4000 Onwards        Pages: 139
    The global Influenza Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Influenza Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type - Whole Virus Vaccines - Split Virus Vaccin......
  • Global Influenza Vaccines Market 2021 - 2027
    Published: 19-Apr-2021        Price: US 3450 Onwards        Pages: 275
    The number of persons being vaccinated with influenza vaccines worldwide will touch the figure of 500 Million by the year-end of 2027 Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccines, the introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most of the countries. Long–term Growth Projection:......
  • Global Avian Influenza Vaccines Sales Market Report 2021
    Published: 06-Apr-2021        Price: US 4000 Onwards        Pages: 139
    The global Avian Influenza Vaccines market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Avian Influenza Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type - Type H5 - Type H9 - ......
  • Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Report 2021
    Published: 01-Apr-2021        Price: US 4000 Onwards        Pages: 134
    The global 23-Valent Pneumococcal Polysaccharide Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global 23-Valent Pneumococcal Polysaccharide Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type......
  • Global Covid-19 Vaccine Market - Analysis By Product Type, Patient Type, End User, By Region, By Country (2021 Edition): Market Insights, Competition and Forecast (2020-2030)
    Published: 31-Mar-2021        Price: US 2000 Onwards        Pages: 214
    Executive Summary Global Covid-19 vaccine Market will be valued at approximately USD 25 billion in the year 2024. The growing government support for vaccine development and the increasing involvement of global organizations in the development of adequate vaccination facilities in endemic regions is anticipated to positively influence the sales of Coronavirus vaccine in the upcoming years. Moreover, the strong demand for coronavirus vaccine, the ongoing initiative initiatives by go......
  • 2020-2025 Global H1N1 Vaccines Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 30-Mar-2021        Price: US 3360 Onwards        Pages: 97
    This report elaborates the market size, market characteristics, and market growth of the H1N1 Vaccines industry, and breaks down according to the type, application, and consumption area of H1N1 Vaccines. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry re......
  • 2020-2025 Global Influenza Vaccine Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 25-Mar-2021        Price: US 3360 Onwards        Pages: 120
    Influenza vaccines, also known as flu shots or flu jabs, are vaccines that protect against infection by influenza viruses... This report elaborates the market size, market characteristics, and market growth of the Influenza Vaccine industry, and breaks down according to the type, application, and consumption area of Influenza Vaccine. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. In Chap......
  • Global Encephalitis Vaccination Market Growth (Status and Outlook) 2021-2026
    Published: 22-Mar-2021        Price: US 3660 Onwards        Pages: 115
    According to this latest study, the 2021 growth of Encephalitis Vaccination will have significant change from previous year. By the most conservative estimates of global Encephalitis Vaccination market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1196.1 million in 2020. Over the next five years the Encephalitis Vaccination market will register a 5.8% CAGR in terms of revenue, the global market size will reach US$ 1499.2 million by 2026. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs